EDSA
Edesa BiotechCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
EDSA still has upside optionality because paridiprubart showed statistically significant mortality benefit in the February 24, 2026 8-K, and the company also has external program support through government-backed funding and study activity [#8-K-2026-02-24] [#10-Q-2026-02-13].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.3.
What can break
Dilutive financing or additional ATM usage
Momentum
99
Value
41
Sentiment
21
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $8.50 · Bear $2.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $14.00
Why
Momentum99 · Δ7d -0.3
Value41 · Δ7d +0.1
Sentiment21 · Δ7d +23.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
99
34% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
21
33% active weight
Current posture
7d trendImproving
Δ7d
+23.2
Δ21d
+23.2
Why this grade
Composite grade C. Momentum 99.4 / Value 41.1 / Sentiment 21.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$59.49M
Beta
0.21
Shares Out
8.33M
P/E (TTM) · Derived
-5.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.54
Rev YoY
-
EPS YoY
-6.6%
Gross Margin
-
Op Margin
-
Net Debt
-$10.79M
Current Ratio
10.67
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology